23.01.2013 • NewsJoerg ReinhardtNovartisBayer

Dr. Joerg Reinhardt to Leave Bayer HealthCare

Dr. Joerg Reinhardt (56), Chairman of the Board of Management of Bayer HealthCare and a member of the Bayer Executive Council, will not renew his contract when it expires in summer 2013. Instead he intends to stand for election as new Director of Swiss healthcare company Novartis and designated non-executive Chairman of the Board at its annual general meeting to be held at the end of February with a view to assuming that office on August 1, 2013. Reinhardt will end his active service with Bayer effective February 28, 2013.

Bayer Management Board member Prof. Wolfgang Plischke (61), whose responsibilities currently include Technology, Innovation and Sustainability, will take over the function of Chairman at Bayer HealthCare in addition to his existing duties until a successor is appointed. Prior to his appointment to the Bayer Board of Management on March 1, 2006, Plischke had worked in the health care field for 25 years, latterly as General Manager of what was then the Pharmaceuticals Business Group.

Joerg Reinhardt has been Chairman of the Board of Management of Bayer HealthCare since August 15, 2010. In April 2012, Reinhardt was appointed to the Board of Directors of Lonza Group, Basel, Switzerland. Lonza is a global company that provides products and services for the life sciences industry. Reinhardt is also a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.